Use of stem cell factor to mobilize hematopoietic progenitors

Current Opinion in Hematology

Volumn 4, Issue 3, 1997, Pages 157-162

  Bearman, Scott I ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; STEM CELL FACTOR;

HEMATOPOIETIC STEM CELL; MAST CELL; MELANOCYTE; PRIORITY JOURNAL; REVIEW; SPERMATOCYTE;

EID: 0030794104     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199704030-00001     Document Type: Review

References (48)

1. To LB, Shepperd KM, Haylock DN, Dyson PG, Charles P, Thorp DL, Dale BM, Dart GW, Roberts MM, Sage RE, et al.: Single high doses of cyclophosphamide enable the collection of high numbers of hemapoietic stem cells from the peripheral blood. Exp Hematol 1990, 18:442-447.
2. Bensinger WI, Longin K, Appelbaum F, Rowley S, Weaver C, Lilleby K, Gooley T, Lynch M, Higano T, Klarnet J, et al.: Peripheral blood stem cells collected after recombinant granulocyte colony-stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994, 87:825-831.
3. Dreger P, Marquardt P, Haferlach T, Jacobs S, Mulverstedt T, Eckstein V, Suttorp M, Loffler H, Muller-Ruchholtz W, Schmitz N: Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product. Br J Cancer 1993, 68:950-957.
4. Russell ES: Hereditary anemias of the mouse: a review for geneticists. Adv Genet 1979, 20:357-459.
5. Russell ES: Abnormalities of erythropoiesis associated with mutant genes in mice. In Regulation of Hematopoiesis. Edited by Gordon AL New York: Appleton-Century Crofts; 1970:649-657.
6. Anderson DM, Lyman SD, Baird A, Wignall JM, Eisenman J, Rauch C, March CJ, Boswell HS, Gimpel SD, Cosman D, et al.: Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell 1990, 63:235-243.
7. Tokoz D, Zsebo KM, Smith KA: Support of human hematopoiesis in long-term bone marrow cultures by murine stromal cells selectively expressing the membrane bound and secreted forms of the human homolog of the steel gene product stem cell factor. Proc Natl Acad Sci U S A 1992, 89:7350-7356.
8. Zsebo KM, Williams DA, Geissler EN, Broudy VC, Martin FH, Atkins HL, Hsu RY, Birkett NC, Okino KH, Murdock DC, et al.: Stem cell factor is encoded at the S/ locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 1990, 63:213-224.
9. Russell ES, Bernstein SE: Influence of non-H-2 genetic factors on success in implantation therapy of W series hereditary anemias of the mouse. Transplantation 1967, 5:142-153.
10. Sheridan WP, McNiece I: Stem cell factor. In High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells, edn 2. Edited by Armitage JO, Antman KH. Baltimore: Williams & Wilkins; 1995:429-441. Well written review of biology and clinical use of stem cell factor.
11. McNiece IK, Langley KE, Zsebo KM: Recombinant human stem cell factor synergizes with GM-CSF, IL-3, and EDO to stimulate human progenitors of the myeloid and erythroid lineages. Exp Hematol 1991, 19:226-231.
12. Hoffman R, Tong J, Brandt J, Traycoff C, Bruno E, McGuire BW, Gordon MS, McNiece I, Srour EF: The in vitro and in vivo effects of stem cell factor on human hematopoiesis. Stem Cells 1993, 11 (suppl 2):76-82.
13. Briddell RA, Bruno E, Cooper RJ, Brandt JE, Hoffman R: Effect of c-kit ligand on in vitro human megakaryocytopoiesis. Blood 1991, 78:2854-2859.
14. Zsebo KM, Smith KA, Hartley CA, Greenblatt M, Cooke K, Rich W, McNiece IK: Radioprotection of mice by recombinant rat stem cell factor. Proc Nat Acad Sci U S A 1992, 89:9464-9468. The authors treated mice with SCF prior to and/or after total body irradiation. Eighty percent of mice who received SCF prior to irradiation had long-term survival whereas mice who did not receive SCF or received SCF after irradiation all died. One hundred percent of mice who were administered SCF both prior to and after irradiation had long-term survival. Bone marrow cellularity decreased to approximately 14% of baseline levels within 3 days of irradiation but increased rapidly in mice who received SCF before and after irradiation. In addition, both mature and primitive marrow progenitors that decreased to less than 1% of baseline levels on day 1 postirradiation increased markedly by 6 days after irradiation in SCF-treated animals.
15. Broudy VC, Smith FO, Lin N, Zsebo KM, Egrie J, Bernstein ID: Blasts from patients with acute myelogenous leukemia express functional receptor for stem cell factor. Blood 1992, 80:60-67.
16. Pinto A, Glohghini A, Gattei V, Aldinucci D, Zagonel V, Carbone A: Expression of the c-kit receptor in human lymphomas is restricted to Hodgkin's disease and CD30+ anaplastic large cell lymphoma. Blood 1994, 83:785-792.
17. Turner AM, Zsebo KM, Martin F, Jacobsen FW, Bennett LG, Broudy VC: Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors. Blood 1992, 80:374-381.
18. Shui C, Khan WB, Leigh BR, Turner AM, Wilder RB, Knox SJ: Effects of stem cell factor on the growth and radiation survival of tumor cells. Cancer Res 1995, 55:3431-3437. Stem cell factor did not stimulate the proliferation of tumor cell lines in culture. However, SCF did increase colony formation by cell lines that expressed the receptor for SCF. When these cells were tranplanted into nude mice, growth of tumor cells was not enhanced by administration of SCF. Finally, SCF did not protect cell lines from 2 GY of irradiation, irrespective of whether the cell lines expressed the receptor for SCF, or protect xenographs of a cutaneous T-cell lymphoma in nude mice.
19. Briddell RA, Hartley CA, Smith KA, McNiece IK: Recombinant rat stem cell factor synergizes with recombinant human granulocyte colony-stimulating factor in vivo in mice to mobilize peripheral blood progenitor cells that have enhanced repopulating potential. Blood 1993, 82:1720-1723.
20. Van X-Q, Briddell RA, Hartley C, Stoney G, Samal B, McNiece I: Mobilization of long-term hematopoietic reconstituting cells in mice by the combination of stem cell factor plus granulocyte colony-stimulating factor. Stood 1994, 84:795-799.
21. de Revel T, Appelbaum FR, Storb R, Schuening F, Nash R, Deeg J, McNiece I, Andrews R, Graham T: Effects of granulocyte colony-stimulating factor and stem cell factor, alone and in combination, on the mobilization of peripheral blood cells that engraft lethally irradiated dogs. Blood 1994, 83:3795-3799.
22. Sandmaier BM, Storb R, Santos EB, Krizanec-Bengez L, Lian T, McSweeney PA, Yu C, Schuening FG, Deeg HJ, Graham T: Allogeneic transplants of canine peripheral blood stem cells mobilized by recombinant canine hematopoietic growth factors. Blood 1996, 87:3508-3513.
23. Andrews RG, Bartelmez SH, Knitter GH, Myerson D, Bernstein ID, Appelbaum FR, Zsebo KM: A c-kit ligand, recombinant human stem cell factor, mediates reversible expansion of multiple CD34+ colony-forming cell types in blood and marrow of baboons. Blood 1992, 80:920-927.
24. Andrews RG, Briddell RA, Knitter GH, Opie T, Bronsden M, Myerson D, Appelbaum FR, McNiece IK: In vivo synergy between recombinant human stem cell factor and recombinant human granulocyte colony-stimulating factor in baboons: enhanced circulation of progenitor cells. Blood 1994, 84:800-810.
25. Crawford J, Lau D, Erwin R, Rich W, McGuire B, Meyers F: A phase I trial of recombinant methionyl human stem cell factor (SCF) in patients (pts) with advanced non-small cell lung carcinoma (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1993, 12:338.
26. Demitri G, Costa J, Hayes D, Sledge G, Galli S, Hoffman R, Merica E, Rich W, Harkins B, McGuire B, et al.: A phase I trial of recombinant methionyl human stem cell factor (SCF) in patients with advanced breast carcinoma pre- and post-chemotherapy (chemo) with cyclophosphamide (C) and doxorubicin (A) [abstract]. Proc Am Soc Clin Oncol 1993, 12:367.
27. Glaspy J, McNiece IK, LeMaistre F, Menchaca D, Briddell R, Lill M, Jones R, Tami L, Morstyn G, Brown S, et al.: Effects of stem cell factor (rhSCF) and filgrastim (rhG-CSF) on the mobilization of peripheral blood progenitor cells (PBPC) and hematological recovery post transplant: early phase I/II study results. Proc Am Soc Clin Oncol 1994, 13:68.
28. Glaspy J, LeMaistre CF, Lill M, Jones R, Moore A, Briddell R, Menchaca D, Turner S, Shpall EJ: Dose-response of 7 days administration of recombinant methionyl human stem cell factor (SCF) in combination with filgrastim (G-CSF) for progenitor cell mobilization in patients with stage II-IV breast cancer [abstract]. Blood 1995, 86:463.
29. Peters WP, Shpall EJ, Jones RB, Olsen GA, Bast RC, Gockerman JP, Moore JO: High-dose combination alkylating agents with bone marrow as initial treatment for metastatic breast cancer. J Clin Oncol 1988, 6:1368-1375.
30. Glaspy J, McNiece IK, LeMaistre F, Menchaca D, Briddell R, Lill M, Jones R, Tami L, Morstyn G, Brown S, et al.: Effects of stem cell factor (rhSCF) and filgrastim (rhG-CSF) on the mobilization of peripheral blood progenitor cells (PBPC) and hematological recovery post transplant: preliminary phase I/II study results [abstract]. Br J Haematol 1994, 87:156.
31. Basser R, Begley CG, Mansfield R, To B, Juttner C, Maher D, Fox R, Cebon J, Szer J, Grigg A, et al.: Mobilization of PBPC by priming with stem cell factor (SCF) before filgrastim compared to concurrent administration [abstract]. Blood 1995, 86(suppl 1):687
32. Tricot G, Jagannath S, Desikan KR, Siegel D, Munshi N, Olson E, Wyres M, Parker W, Barlogie B: Superior mobilization of peripheral blood progenitor cells (PBPC) with r-metHu-SCF (SCF) and r-metHuG-CSF (filgrastim) in heavily pretreated multiple myeloma (MM) patients. Blood 1996, 88(suppl 1):388a.
33. Weaver A, Slowley C, Woll PJ, Lind M, Jenkins B, Gill C, Wilkinson PM, Dexter TM, Testa NG, Crowther D: A randomized comparison of progenitor cell mobilization using chemotherapy plus stem cell factor (r-metHuSCF) and filgrastim (r-metHuG-CSF) or chemotherapy plus filgrastim. Proc Am Soc Clin Oncol 1996, 15:269.
34. Moskowitz C, Stiff P, Gordon M, Gabrilove J, Bayer R, Broun R, Nichols C, Ho AD, Wyres M, Nimer S, et al.: The influence of extensive prior chemotherapy on the mobilization of peripheral blood progenitor cells (PBPC) using stem cell factor (rhSCF) and filgrastim (rmetHuG-CSF) and on hematologic recovery post cyclophosphamide, BCNU, and VP-16 (CBV) in patients (pts) with relapsed non-Hodgkin's lymphoma (NML): an interim analysis [abstract]. Blood 1994, 84(suppl 1):107. The authors studied the mobilization of PBPC in heavily pretreated patients with malignant lymphoma. They demonstrated that, in heavily pretreated patients, the combination of SCF plus G-CSF resulted in mobilization of twice as many cells as G-CSF alone.
35. Bradley BA, Hows JM, Gore SM, Bidwell JL, Clay T, Downie TR, Gluckman E, Howard MR, Laundy GL: Current status of unrelated donor bone marrow transplantation: the International Marrow Unrelated Search and Transplant (IMUST) Study. Clin Transplants 1992:91-107.
36. Kurtzberg J, Laughlin M, Graham ML, Smith C, Olsen JF, Halperin EC, Ciooci G, Carrier C. Stevens CE, Rubenstein P: Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996, 335:157-166.
37. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J Jr, Anderson WF, Ihle JN: Gene-marking to trace origin of relapse after autololgous bone-marrow transplantation. Lancet 1993, 341:85-86. This report is the first definitive study documenting that tumor cells in the graft can contribute to relapse after autologous marrow transplantation. The authors marked marrow cells (and occult contaminating tumor cells) with the gene for neomycin resistance and followed patients until relapse. Malignant cells from two patients who relapsed after autologous marrow transplant contained the neomycin-resistance gene.
38. Eipers PG, Krauss JC, Palsson BO, Emerson SG, Todd RF III, Clarke MF: Retroviral-mediated gene transfer in human bone marrow cells grown in continuous perfusion culture vessels. Blood 1995, 86:3754-3762.
39. Zimmerman T, Williams SF, Bender JG, Lee WJ, Blake M, Carreon J, Swinney P, Smith SJ, Schilling M, Oldham F, et al.: Clinical use of selected and expanded CD34+ cells: a preliminary report of feasibility and safety. J Hemato Ther 1995, 4:527-529.
40. Emerson SG: Ex vivo expansion of hematopoietic precursors, progenitors, and stem cells: the next generation of cellular therapeutics. Blood 1996, 87:3082-3088. This is an excellent review of ex vivo expansion of hematopoietic progenitors. The paper discusses both bioreactor and liquid culture methodologies and suggests how such cells might be applied.
41. Silver SM, Adams PT, Hutchinson RJ, Douville JW, Paul LA, Clarke MF, Palsson BO, Emerson EG: Phase I evaluation of ex vivo expanded hematopoietic cells produced by perfusion culture in autologous bone marrow transplantation (ABMT) [abstract]. Blood 1993, 82:297.
42. Purdy MH, Hogan CJ, Hami L, McNiece I, Franklin W, Jones RB, Bearman SI, Berenson RJ, Cagnoni PJ, Heimfeld S, et al.: Large volume ex vivo expansion of CD34-positlve hematopoietic progenitor cells for transplantation. J Hematother 1995, 4:515-525.
43. + progenitors. This study did not, however, definitively demonstrate that hematopoietic recovery was due to the expanded cells, as it is unclear whether the regimen of etoposide, ifosfamide, carboplatin, and epirubicin is completely myeloablative.
44. Min Y-H, Law P, Young D, Huang S, Ho AD: Generation of large numbers of functional dendritic cells from mobilized CD34+ peripheral blood cells harvested from healthy donors [abstract]. Blood 1996, 88(suppl 1):190.
45. Ombrosi L, Barulli S, Rupoli S, Olivieri A, Offidani M, Masia MC, Montanari M, Scalari P, Montroni M, Mancini S, et al.: Ex vivo expansion of dendritic cells for immunotherapy: optimization of the experimental conditions for their generation from blood progenitor cells [abstract]. Blood 1996, 88(suppl 1):111.
46. + progenitors contaminated with epithelial tumor cells conferred a proliferative advantage to the hematopoietic progenitors. The limitation of this paper is that the tumor cells cultured in these experiments were from established cell lines. How tumor cells that endogenously contaminate hematopoietic progenitors behave in expansion cultures is uncertain.
47. Miller DG, Adam MA, Miller AD: Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990, 10:4239-4342.
48. Nolta JA, Crooks GM, Overell RW, Williams DE, Kohn DB: Retroviral vector-mediated gene transfer into primitive human hematopoietic progenitor cells: effects of mast cell growth factor (MGF) combined with other cytokines. Exp Hematol 1992, 20:1065-1071.